DR. FRANCIS VINCENT CHISARI, MD
Medical Practice at Crest Rd, Del Mar, CA
License number
California G25675
Category
Osteopathic Medicine
Type
Internal Medicine
License number
California G25675
Category
Medical Practice
Type
Immunopathology
Address
Address
1010 Crest Rd, Del Mar, CA 92014
Phone
(858) 755-7661
Professional information
Peptides For Inducing Cytotoxic T Lymphocyte Responses To Hepatitis B Virus
US Patent:
5840303, Nov 24, 1998
Filed:
Jun 6, 1995
Appl. No.:
8/468279
Inventors:
Francis V. Chisari - Del Mar CA
Carlo Ferrari - Parma, IT
Amalia Penna - Parma, IT
Gabriele Missale - Parma, IT
Carlo Ferrari - Parma, IT
Amalia Penna - Parma, IT
Gabriele Missale - Parma, IT
Assignee:
The Scripps Research Foundation - La Jolla CA
International Classification:
A61K 3929, A61K 3912, A61K 39385, C07K 706
US Classification:
4241891
Abstract:
Peptides are used to define epitopes that stimulate HLA-restricted cytotoxic T lymphocyte activity against hepatitis B virus antigens. The peptides are derived from regions of HBV nucleocapsid, envelope, polymerase and the transcriptional transactivator X protein, and are particularly useful in treating or preventing HBV infection, including methods for stimulating the immune response of chronically infected individuals to respond to HBV antigens. Pharmaceutical compositions and hepatitis B vaccines which comprise the peptides and physiologically acceptable carriers can be employed in conjunction with other HBV vaccines to provide more effective immunity against the disease. Methods for identifying individuals who are particularly susceptible to developing chronic HBV infection and who can be targeted for treatment by the CTL peptides are also provided.
Hepatitis C Virus-Derived Peptides Capable Of Inducing Cytotoxic T Lymphocyte Responses
US Patent:
5709995, Jan 20, 1998
Filed:
Mar 17, 1994
Appl. No.:
8/214650
Inventors:
Francis V. Chisari - Del Mar CA
Andreas Cerny - La Jolla CA
Andreas Cerny - La Jolla CA
Assignee:
The Scripps Research Institute - La Jolla CA
International Classification:
C12Q 170, A61K 3804, A61K 3929
US Classification:
435 5
Abstract:
The hepatitis C virus (HCV) is the major cause of non-A, non-B vital hepatitis. The most striking feature of HCV induced liver disease is its tendency toward chronicity and slowly progressive liver cell injury. HLA Class I-restricted cytotoxic T lymphocyte (CTL) responses are considered to be a sine qua non for the effective clearance of vital infections. However, the characteristics of HCV-specific cytotoxic effector cells and identification of their cognate target antigens remains to be elucidated. This invention discloses novel HCV-derived peptides that are recognized by patient CTL. Peripheral blood mononuclear cells (PBMC) were obtained from HLA-A2 positive patients with chronic HCV infection and stimulated with HCV-derived peptides. Effector cells were tested for their ability to lyse HLA-A2-matched target cells sensitized either with a peptide or a vaccinia virus construct containing HCV sequences. Immunogenic HCV CTL peptides were identified in the putative core protein and nonstructural proteins (e. g. , NS3-5).
Peptides For Inducing Cytotoxic T Lymphocyte Responses To Hepatitis B Virus
US Patent:
6235288, May 22, 2001
Filed:
Jun 5, 1995
Appl. No.:
8/463486
Inventors:
Francis V. Chisari - Del Mar CA
Assignee:
The Scripps Research Institute - La Jolla CA
International Classification:
A61K 3929
US Classification:
4242271
Abstract:
Peptides are used to define epitopes that stimulate HLA-restricted cytotoxic T lymphocyte activity against hepatitis B virus antigens. The peptides are derived from regions of HBV envelope, and are particularly useful in treating or preventing HBV infection, including methods for stimulating the immune response of chronically infected individuals to respond to HBV antigens.
Peptides For Inducing Cytotoxic T Lymphocyte Responses To Hepatitis B Virus
US Patent:
5932224, Aug 3, 1999
Filed:
Jun 6, 1995
Appl. No.:
8/469830
Inventors:
Francis V. Chisari - Del Mar CA
Assignee:
The Scripps Research Institute - La Jolla CA
International Classification:
A61K 3929, A61K 4744, A61K 3808, A61K 3810
US Classification:
4242271
Abstract:
Peptides are used to define epitopes that stimulate HLA-restricted cytotoxic T lymphocyte activity against hepatitis B virus antigens. The peptides are derived from regions of HBV polymerase, and are particularly useful in treating or preventing HBV infection, including methods for stimulating the immune response of chronically infected individuals to respond to HBV antigens.
Peptides For Inducing Cytotoxic T Lymphocyte Responses To Hepatitis B Virus
US Patent:
7744898, Jun 29, 2010
Filed:
Sep 8, 2005
Appl. No.:
11/221470
Inventors:
Francis V. Chisari - Del Mar CA, US
Assignee:
The Scripps Research Institute - La Jolla CA
International Classification:
A61K 39/29, C07K 14/02, C07K 7/06, C07K 4/02
US Classification:
4241891, 42419611, 4242271, 530328, 530300
Abstract:
Peptides are used to define epitopes that stimulate HLA-restricted cytotoxic T lymphocyte activity against hepatitis B virus antigens. The peptides are derived from regions of HBV polymerase, and are particularly useful in treating or preventing HBV infection, including methods for stimulating the immune response of chronically infected individuals to respond to HBV antigens.
Peptides For Inducing Cytotoxic T Lymphocyte Responses Hepatitis B Virus
US Patent:
5788969, Aug 4, 1998
Filed:
Jun 5, 1995
Appl. No.:
8/464235
Inventors:
Francis V. Chisari - Del Mar CA
Assignee:
The Scripps Research Institute - La Jolla CA
International Classification:
A61K 3929, A61K 3912, A61K 39385, C07K 706
US Classification:
4241891
Abstract:
Peptides are used to define epitopes that stimulate HLA-restricted cytotoxic T lymphocyte activity against hepatitis B virus antigens. The peptides are derived from regions of HBV envelope, and are particularly useful in treating or preventing HBV infection, including methods for stimulating the immune response of chronically infected individuals to respond to HBV antigens.
Peptides For Inducing Cytotoxic T Lymphocyte Responses To Hepatitis B Virus
US Patent:
7368118, May 6, 2008
Filed:
Feb 28, 2005
Appl. No.:
11/068710
Inventors:
Francis V. Chisari - Del Mar CA, US
Assignee:
The Scripps Research Institute - La Jolla CA
International Classification:
A61K 39/00, A61K 39/29, A61K 38/00, A61K 38/04
US Classification:
4242271, 4241891, 530324, 530328
Abstract:
Peptides are used to define epitopes that stimulate HLA-restricted cytotoxic T lymphocyte activity against hepatitis B virus antigens. The peptides are derived from regions of HBV envelope, and are particularly useful in treating or preventing HBV infection, including methods for stimulating the immune response of chronically infected individuals to respond to HBV antigens.
Peptides For Inducing Cytotoxic T Lymphocyte Responses To Hepattis B Virus
US Patent:
5780036, Jul 14, 1998
Filed:
Apr 4, 1995
Appl. No.:
8/416950
Inventors:
Francis V. Chisari - Del Mar CA
Assignee:
The Scripps Research Institute - La Jolla CA
International Classification:
A61K 3929, A61K 3912, A61K 39385, C07K 706
US Classification:
4241891
Abstract:
Peptides are used to define epitopes that stimulate HLA-restricted cytotoxic T lymphocyte activity against hepatitis B virus antigens. The peptides are derived from regions of HBV polymerase, and are particularly useful in treating or preventing HBV infection, including methods for stimulating the immune response of chronically infected individuals to respond to HBV antigens.
Peptides For Inducing Cytotoxic T Lymphocyte Responses To Hepatitis B Virus
US Patent:
2003017, Sep 11, 2003
Filed:
Feb 5, 2003
Appl. No.:
10/359431
Inventors:
Francis Chisari - Del Mar CA, US
Assignee:
The Scripps Research Institute - La Jolla CA
International Classification:
A61K039/29, A61K045/00, A61K047/44, C07K005/00, C07K007/00, C07K016/00, C07K017/00, A61K038/04
US Classification:
530/328000, 424/227100, 530/327000, 424/283100
Abstract:
Peptides are used to define epitopes that stimulate HLA-restricted cytotoxic T lymphocyte activity against hepatitis B virus antigens. The peptides are derived from regions of HBV polymerase, and are particularly useful in treating or preventing HBV infection, including methods for stimulating the immune response of chronically infected individuals to respond to HBV antigens.
Peptides For Inducing Cytotoxic T Lymphocyte Responses To Hepatitis B Virus
US Patent:
2004024, Dec 2, 2004
Filed:
Jun 29, 2004
Appl. No.:
10/881453
Inventors:
Francis Chisari - Del Mar CA, US
International Classification:
A61K048/00, A61K039/29, C12N015/86
US Classification:
424/093200, 424/227100, 435/456000
Abstract:
Peptides are used to define epitopes that stimulate HLA-restricted cytotoxic T lymphocyte activity against hepatitis B virus antigens. The peptides are derived from regions of HBV envelope, and are particularly useful in treating or preventing HBV infection, including methods for stimulating the immune response of chronically infected individuals to respond to HBV antigens.